Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $3.2 million.

  • Arcturus Therapeutics Holdings' Non Operating Income fell 1529.6% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 3751.79%. This contributed to the annual value of $15.2 million for FY2024, which is 841.42% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Non Operating Income stood at $3.2 million, which was down 1529.6% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Non Operating Income peaked at $6.9 million during Q4 2023, and registered a low of -$564000.0 during Q1 2022.
  • In the last 5 years, Arcturus Therapeutics Holdings' Non Operating Income had a median value of $2.6 million in 2025 and averaged $2.0 million.
  • In the last 5 years, Arcturus Therapeutics Holdings' Non Operating Income tumbled by 228181.82% in 2021 and then surged by 134018.69% in 2023.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Non Operating Income stood at -$524000.0 in 2021, then soared by 295.61% to $1.0 million in 2022, then skyrocketed by 571.32% to $6.9 million in 2023, then plummeted by 53.29% to $3.2 million in 2024, then increased by 0.62% to $3.2 million in 2025.
  • Its Non Operating Income stands at $3.2 million for Q3 2025, versus $2.6 million for Q2 2025 and $2.8 million for Q1 2025.